Targeting cysteinyl leukotriene receptor 1 reprograms tumor-promoting myelopoiesis and overcomes immune checkpoint therapy resistance
19 May 2026 at 08:00
Nature Cancer, Published online: 19 May 2026; doi:10.1038/s43018-026-01174-7
Tang et al. identify cysteinyl leukotriene receptor 1 (CysLTR1) as a critical regulator of tumor-induced myelopoiesis, suggesting CysLTR1 targeting to sensitize tumors to immune checkpoint blockade.